Melanoma
11 – 20 of 82
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
BioMEL : a translational research biobank of melanocytic lesions and melanoma
- Contribution to journal › Article
- 2023
-
Mark
Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells
- Contribution to journal › Article
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
- Contribution to journal › Article
- 2022
-
Mark
Transcriptomic signatures of tumors undergoing T cell attack
- Contribution to journal › Article
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
- Contribution to journal › Article
-
Mark
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
- Contribution to journal › Article
-
Mark
Desmoglein-2 is important for islet function and β-cell survival
- Contribution to journal › Article
-
Mark
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
- Contribution to journal › Article
-
Mark
B Cells and Tertiary Lymphoid Structures : Friends or Foes in Cancer Immunotherapy?
- Contribution to journal › Scientific review
- 2021
-
Mark
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
- Contribution to journal › Article
